The clinicians obviously know which trial arm a patient is in, but with 28 active clinical sites and patients spread amongst those sites, no one clinician has enough patients to understand efficacy. The company itself is also fully blinded, so we have no idea as to how it’s going at this time.
Their is an arm to the trial with Lucentis and I believe the idea of Ph2 is to prove that the combined drug would have the same results as iCo with less frequent injections.
BTW, ICo owns 6% of IMNP (trading on Nasdaq) at 50 million mcap and they outlicensed a drug from iCo.
Feel free to contact the Company's IR for any more specific questions.
Michael Moore
Vice President, United States
TMX Equicom, Investor Relations
T: (858) 886-7813
C: (619) 302-4431
mmoore@tmxequicom.com
